Stop wasting hours on dense SEC filings. Get AI-powered summaries of any SEC Filings in seconds. Understand key insights and risks, fast.
Currently we only process Form 8-K, 6-K, 3, 4, 144, Schedule 13D and Schedule 13G. We will support more forms in the future.
Filter by Form Type:
Industry:Biotechnologyβ
2026-09-09CYBNSCHEDULE 13DCybin Inc. Chief Growth Officer Paul Glavine Reports 5.8% Ownership StakeHIGH
Paul Glavine, the Chief Growth Officer of Cybin Inc. (CYBN), filed a Schedule 13D on September 9, 2026, reporting a 5.8% ownership stake in the company. The filing indicates that Glavine, along with the PLG Family Trust, holds a total of 4,407,456 common shares. This position was established through a combination of pe...
Biotechnologyownership +5.80%
2026-09-09CYBNSCHEDULE 13DExecutive Chair Eric So Increases Stake in Cybin Inc. to 5.8% via Market Purchase and RSU AwardHIGH
On September 9, 2026, Eric So, the Executive Chair and co-founder of Cybin Inc. (ticker: CYBN), filed a Schedule 13D reporting a significant increase in his ownership position. As of the event date on September 1, 2026, the reporting persons collectively hold 4,423,894 common shares, representing a 5.8% stake in the co...
Biotechnologyownership +5.80%
2026-09-09CYBIN INC.SCHEDULE 13DCybin Inc. Chief Growth Officer Paul Glavine Reports 5.8% Ownership StakeDuplicateHIGH
Paul Glavine, the Chief Growth Officer of Cybin Inc. (CYBN), filed a Schedule 13D on September 9, 2026, reporting a 5.8% ownership stake in the company. The filing indicates that Glavine, along with the PLG Family Trust, holds a total of 4,407,456 common shares. This position was established through a combination of pe...
Biotechnologyownership +5.80%